摘要
目的评价吉西他滨联合顺铂治疗晚期膀胱癌的疗效和安全性。方法32例Ⅳ期膀胱癌接受吉西他滨联合顺铂方案化疗：吉西他滨1200mg/m^2,第1天和第8天,顺铂25mg/m^2,第1-3天,21天为1个周期。结果32例患者中完全缓解4例,部分缓解13例,有效率为53.1%,中位肿瘤进展时间（TTP）8.5个月,中位生存时间为14个月,1年生存率58.3%。毒性反应主要为血液学毒性、消化道反应。结论吉西他滨联合顺铂3周方案是治疗晚期膀胱癌安全、有效的化疗方案。
Objective To evaluate the efficacy and safety of a combination of gemeitahine with eisplatin in treatment of patients with stage Ⅳbladder cancer. Methods Thirty two patients with metastatic bladder cancer were treated with gemcitabine 1200mg/m^2 on d1, d8 and cisplatin 25 mg/m^2 on d1-3. Cycles were repeated every 3 weeks. Results Of 32 assessable patients, an overall response rate of 53.1% was observed, including 4 complete response and 13 partial response. Median time of progression was 8.5 months, median survival time was 14 months, and 1-year survival rate was 58.3%. The main toxic response was myleosuppression, nausea/vomiting. Conclusion Three-week regimen of gemcitabine combined with cisplatin is safe and effective for patients with stage Ⅳ bladder cancer.
出处
《实用肿瘤杂志》
CAS
2008年第2期175-177,共3页
Journal of Practical Oncology
